“Our goal is to identify memory issues at the earliest possible stages,” said study author Ronald C. Petersen, MD, PhD, of Mayo Clinic in Rochester, Minn., and a member of the American Academy of Neurology. “Understanding what factors can help us predict who will develop this initial stage of memory and thinking problems, called mild cognitive impairment (MCI), is crucial, because people with MCI have an increased risk of developing dementia.” The study involved 1,449 randomly selected people from Olmsted County, Minn., between the ages of 70 and 89 who did not have memory and thinking problems. At the start of the study and at visits every 15 months for an average of 4.8 years, participants were given memory and thinking tests.
During the study, 401 people, or 28 percent, developed mild cognitive impairment. The scoring system took into account factors that could be easily obtained from medical records, such as years of education, history of stroke or diabetes, and smoking.
Researchers also factored in information obtained at the clinic visit, such as a test of thinking abilities and symptoms of depression and anxiety. Factors were assigned a score based on how much they contributed to the risk of developing thinking problems. For example, being diagnosed with diabetes before age 75 increased the risk score by 14 points, while having 12 or fewer years of education increased the risk by two points. When the women’s scores were divided into four groups, the lowest group had risk scores of less than 27 and the highest had scores of more than 46. For both men and women, those in the highest group of risk scores were seven times more likely to develop mild cognitive impairment than those in the lowest group. Age, heart health risk factors, depression and anxiety disorders, and memory or functional abilities at the start of the study contributed most to the risk score. The APOE gene, which has been linked to a higher risk of dementia, was determined in the study to be only a moderate risk factor. “This risk scale may be an inexpensive and easy way for doctors to identify people who should undergo more advanced testing for memory issues or may be better candidates for clinical trials,” said Petersen. The study was supported by the National Institutes of Health, the Robert Wood Johnson Foundation, the Robert H. and Clarice Smith and Abigail van Buren Alzheimer’s Disease Research Program and the Rochester Epidemiology Project. To learn more about dementia, please visit www.aan.com/patients.
The American Academy of Neurology, an association of more than 28,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy.